Ameriprise Financial Inc. acquired a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 408,058 shares of the company's stock, valued at approximately $649,000. Ameriprise Financial Inc. owned 0.45% of Caribou Biosciences as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in Caribou Biosciences by 28.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock worth $3,360,000 after purchasing an additional 467,738 shares in the last quarter. Northern Trust Corp boosted its position in Caribou Biosciences by 3.4% during the 4th quarter. Northern Trust Corp now owns 714,737 shares of the company's stock valued at $1,136,000 after acquiring an additional 23,531 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Caribou Biosciences by 74.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company's stock valued at $297,000 after acquiring an additional 79,636 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Caribou Biosciences during the 4th quarter valued at $288,000. Institutional investors own 77.51% of the company's stock.
Caribou Biosciences Stock Up 15.6%
Shares of NASDAQ:CRBU traded up $0.17 during trading on Friday, reaching $1.26. 2,027,432 shares of the company's stock traded hands, compared to its average volume of 1,401,168. Caribou Biosciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The firm has a market cap of $117.19 million, a PE ratio of -0.76 and a beta of 2.44. The company has a 50-day simple moving average of $0.89 and a 200-day simple moving average of $1.30.
Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $1.48 million. On average, equities research analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and issued a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th.
View Our Latest Stock Report on CRBU
Caribou Biosciences Profile
(
Free Report)
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Stories

Before you consider Caribou Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.
While Caribou Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.